APOE and Alzheimer disease: Thus, as the apoE-derived antagonistic peptide, 6KApoEp, might be expected to be particularly beneficial for patients with AD who are either apoE3 or apoE4 isoform carriers, we initially aimed at examining the apoE isoform-specific effect of 6KApoEp therapy.